

## **Vorschlag für ein Promotionsprojekt im Rahmen des VorSPrUNG-Programms**

Hauptbetreuer (➔ VorSPrUNG-Konzept):

Prof. Dr. Martin Weber

Titel des Projektes:

Calcium metabolism influences T cell-driven MS pathogenesis – a novel target in MS?

Abstract:

The exact cause of MS is still unknown; however, it is considered to be an autoimmune-mediated disease triggered by environmental, genetic or infectious factors or a combination of these. First lines of evidence indicate that also calcium influences the course of MS. Calcium ions are essential second messengers involved in the activation of calcineurin and nuclear import of NFATc proteins, which regulate immune-response genes encoding for cell proliferation, differentiation, migration and production of cytokines. Several studies suggest that extracellular calcium influx, via voltage-gated calcium channels contributes to white matter damage in acute spinal cord injury and stroke. In EAE, administration of calcium channel blockers ameliorated disease, decreased microglial proinflammatory activity, fostered remyelination and induced microglia-specific apoptosis. Furthermore, in a recently published case series of 21 MS patients hypercalcemia after high dose vitamin D treatment was associated with neurologic deterioration including new relapses and enhanced MRI activity. This is in line with our own work in which a set of experiments suggested that calcium directly enhances activation and pro-inflammatory differentiation of T cells. In light of the above mentioned findings and this preliminary work calcium seems to play an important role in the pathogenesis of EAE and MS and in other T cell-driven diseases.

In this present project, we will specify the role of calcium in the pathogenesis of MS. In particular, we will investigate whether calcium by itself enhances activation and pro-inflammatory differentiation of T cells and other immune cells using flow cytometry. Due to the limited number of MS patients with different serum calcium levels, we will analyze the effects of calcium on PBMCs isolated from patients with hypertension, which are receiving a calcium antagonist therapy. The results will be compared to hypertensive patients without a calcium antagonist treatment (horizontal study), but also to samples from the individual patient taken at different time points (longitudinal study). To control calcium as well as the possible effects on calcium homeostasis induced by vitamin D, we will measure the serum concentrations of calcium, sodium, phosphate, calcineurin, parathyroid hormone (PTH) and vitamin D (25-OH-D).

In perspective, to control calcium level could prove to be a promising new therapeutic target in MS patients as it has no side effects, is easy to perform and is cost-effective.